GlaxoSmithKline has dismissed Jiangwu Zang, the company’s head of R&D in China after discovering that a study by some of its Chinese scientists contained misrepresentation of data. According to a company statement, three other individuals have been placed on administrative leave, and another employee has resigned. The decision follows an investigation about a scientific paper published in the journal Nature Medicine in 2010 involving preclinical research into multiple sclerosis. Mr. Zang was...